Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Esophagus. 2021 Jul;18(3):604-611. doi: 10.1007/s10388-021-00815-3. Epub 2021 Jan 28.
Endoscopic ultrasonography (EUS) is reportedly the reliable modality to predict the depth of esophageal squamous cell carcinoma (ESCC), however, most previous studies are retrospective or single-centered. We aimed to evaluate the diagnostic ability of conventional endoscopy and EUS using the data from a multicenter prospective study of endoscopic resection (ER) followed by chemoradiotherapy for cSM1-2N0M0 ESCC (JCOG0508).
All lesions were evaluated as cSM cancer with both conventional endoscopy and EUS before enrollment and judged as cSM1 or cSM2 in real time. We compared the clinical and pathological diagnoses for tumor depth and assessed the positive predictive value (PPV) for pSM (pSM/cSM) as the primary endpoint. We also investigated the clinical factors affecting the pathological depth of SM.
175 lesions were examined, and clinical diagnosis was SM1 in 114 and SM2 in 61 lesions. The pathological diagnoses of the epithelium, lamina propria mucosa, muscularis mucosae, SM1, and SM2 were 3, 31, 55, 17, and 69. The PPV for pSM was 49.1% (86/175) in all lesions, 34.2% (39/114) in cSM1 lesions, and 77.0% (47/61) in cSM2 lesions. Multivariable analysis demonstrated that cSM2 (vs. cSM1, OR 6.79) was an independent clinical factor associated with pSM.
While the accurate depth diagnosis in cSM ESCC was difficult to make, the clinical diagnosis of SM2 with both conventional endoscopy and EUS was significantly associated with pSM. Furthermore, diagnostic ER could be recommended to confirm the pathological diagnosis especially in cSM1 lesions with both conventional endoscopy and EUS.
内镜超声检查(EUS)据报道是预测食管鳞状细胞癌(ESCC)深度的可靠方式,然而,大多数先前的研究都是回顾性或单中心的。我们旨在使用来自多中心前瞻性研究(JCOG0508)的内镜切除(ER)后进行放化疗的 cSM1-2N0M0 ESCC 数据评估常规内镜和 EUS 的诊断能力。
所有病变均在入组前通过常规内镜和 EUS 评估为 cSM 癌,并实时判断为 cSM1 或 cSM2。我们比较了肿瘤深度的临床和病理诊断,并评估了 pSM 的阳性预测值(PPV)(pSM/cSM)作为主要终点。我们还研究了影响 SM 病理深度的临床因素。
共检查了 175 个病变,临床诊断为 SM1 的病变 114 个,SM2 的病变 61 个。上皮、固有层黏膜、黏膜肌层、SM1 和 SM2 的病理诊断分别为 3、31、55、17 和 69。所有病变的 pSM 的 PPV 为 49.1%(86/175),cSM1 病变为 34.2%(39/114),cSM2 病变为 77.0%(47/61)。多变量分析表明,cSM2(vs. cSM1,OR 6.79)是与 pSM 相关的独立临床因素。
虽然难以准确诊断 cSM ESCC 的深度,但常规内镜和 EUS 诊断的 SM2 与 pSM 显著相关。此外,特别是在常规内镜和 EUS 检查为 cSM1 的病变中,推荐进行诊断性 ER 以确认病理诊断。